# Alpha Pro Tech Ltd: overview APT · NYSE · CIK 884269 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/apt.md) · [Financials](/companies/apt/financials.md) · [Filings](/companies/apt/filings.md) · [Insiders](/companies/apt/insiders.md) Latest reported revenue: [$18.7m](/filings/0001437749-26-026551.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-026551). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.3](/filings/0001437749-25-033545.md) | [13.8 d](/filings/0001437749-26-007797.md) | [13.8](/filings/0001437749-26-015456.md) | [16.7](/filings/0001437749-26-026551.md) | [14.8](/filings/0001437749-25-033545.md) | [13.9 d](/filings/0001437749-26-007797.md) | [14.6](/filings/0001437749-26-015456.md) | [18.7](/filings/0001437749-26-026551.md) | | Gross margin | % | [38.5%](/filings/0001437749-25-033545.md) | [37.6% d](/filings/0001437749-26-007797.md) | [39.0%](/filings/0001437749-26-015456.md) | [36.8%](/filings/0001437749-26-026551.md) | [39.7%](/filings/0001437749-25-033545.md) | [37.1% d](/filings/0001437749-26-007797.md) | [37.8%](/filings/0001437749-26-015456.md) | [37.4%](/filings/0001437749-26-026551.md) | | Operating margin | % | [5.2%](/filings/0001437749-25-033545.md) | [4.9% d](/filings/0001437749-26-007797.md) | [3.3%](/filings/0001437749-26-015456.md) | [8.0%](/filings/0001437749-26-026551.md) | [7.4%](/filings/0001437749-25-033545.md) | [6.9% d](/filings/0001437749-26-007797.md) | [4.0%](/filings/0001437749-26-015456.md) | [10.8%](/filings/0001437749-26-026551.md) | | Net margin | % | [6.0%](/filings/0001437749-25-033545.md) | [6.1% d](/filings/0001437749-26-007797.md) | [4.4%](/filings/0001437749-26-026551.md) | [7.5%](/filings/0001437749-26-026551.md) | [6.6%](/filings/0001437749-25-033545.md) | [5.0% d](/filings/0001437749-26-007797.md) | [4.8%](/filings/0001437749-26-026551.md) | [9.8%](/filings/0001437749-26-026551.md) | | Diluted EPS | $ per share | [0.08](/filings/0001437749-25-033545.md) | not reported | [0.06](/filings/0001437749-26-015456.md) | [0.12](/filings/0001437749-26-026551.md) | [0.09](/filings/0001437749-25-033545.md) | not reported | [0.07](/filings/0001437749-26-015456.md) | [0.18](/filings/0001437749-26-026551.md) | | Free cash flow | $m | [3.2 d](/filings/0001437749-25-033545.md) | [1.0 d](/filings/0001437749-26-007797.md) | [(4.1)](/filings/0001437749-26-015456.md) | [2.0 d](/filings/0001437749-26-026551.md) | [3.8 d](/filings/0001437749-25-033545.md) | [0.1 d](/filings/0001437749-26-007797.md) | [(0.1)](/filings/0001437749-26-015456.md) | [2.1 d](/filings/0001437749-26-026551.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [68.6](/filings/0001437749-23-006845.md) | [62.0](/filings/0001437749-24-007539.md) | [61.2](/filings/0001437749-25-007218.md) | [57.8](/filings/0001437749-26-007797.md) | [59.1](/filings/0001437749-26-007797.md) | | Gross margin | % | [36.9%](/filings/0001437749-23-006845.md) | [35.0%](/filings/0001437749-24-007539.md) | [37.3%](/filings/0001437749-25-007218.md) | [39.6%](/filings/0001437749-26-007797.md) | [38.1%](/filings/0001437749-26-007797.md) | | Operating margin | % | [11.5%](/filings/0001437749-23-006845.md) | [7.5%](/filings/0001437749-24-007539.md) | [6.7%](/filings/0001437749-25-007218.md) | [6.0%](/filings/0001437749-26-007797.md) | [6.5%](/filings/0001437749-26-007797.md) | | Net margin | % | [9.8%](/filings/0001437749-23-006845.md) | [5.3%](/filings/0001437749-24-007539.md) | [6.8%](/filings/0001437749-25-007218.md) | [6.8%](/filings/0001437749-26-007797.md) | [6.0%](/filings/0001437749-26-007797.md) | | Diluted EPS | $ per share | [0.50](/filings/0001437749-23-006845.md) | [0.26](/filings/0001437749-24-007539.md) | [0.35](/filings/0001437749-25-007218.md) | [0.35](/filings/0001437749-26-007797.md) | [0.33](/filings/0001437749-26-007797.md) | | Free cash flow | $m | [(3.0)](/filings/0001437749-23-006845.md) | [3.8](/filings/0001437749-24-007539.md) | [7.7](/filings/0001437749-25-007218.md) | [1.9](/filings/0001437749-26-007797.md) | [1.7](/filings/0001437749-26-007797.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/apt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [NEEDHAM INVESTMENT MANAGEMENT LLC](/funds/1167212.md) | 2026-06-30 | $3.6m | 642,500 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $3.2m | 561,572 | | Added +17,500 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.9m | 512,476 | | Reduced −41,198 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.6m | 278,687 | | Added +6,887 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $1.5m | 272,300 | Call | Added +75,200 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.4m | 242,699 | | Added +101,473 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $1.3m | 239,500 | Put | Reduced −348,700 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.3m | 232,200 | Call | Reduced −13,600 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $848.1k | 150,900 | Put | Added +117,800 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $770.5k | 137,103 | | Reduced −232 | ## Recent filings [All 530 filings](/companies/apt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-16 | 16:07 ET | [8-K](/filings/0001437749-26-030517.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001437749-26-030517 | | 2026-08-07 | 19:14 ET | [10-Q](/filings/0001437749-26-026551.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026551 | | 2026-08-06 | 14:43 ET | [8-K](/filings/0001437749-26-026101.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026101 | | 2026-06-15 | 20:47 ET | [8-K](/filings/0001437749-26-020665.md) | 5.07 Shareholder vote results | 0001437749-26-020665 | | 2026-05-07 | 16:24 ET | [10-Q](/filings/0001437749-26-015456.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015456 | | 2026-05-07 | 13:01 ET | [8-K](/filings/0001437749-26-015366.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-015366 | | 2026-04-30 | 13:00 ET | [DEF 14A](/filings/0001437749-26-014020.md) | Proxy statement, period 2026-06-10 | 0001437749-26-014020 | | 2026-03-11 | 21:31 ET | [10-K](/filings/0001437749-26-007797.md) | Annual report, period 2025-12-31 | 0001437749-26-007797 | | 2026-03-11 | 20:32 ET | [8-K](/filings/0001437749-26-007775.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-007775 | | 2025-11-06 | 18:23 ET | [10-Q](/filings/0001437749-25-033545.md) | Quarterly report, period 2025-09-30 | 0001437749-25-033545 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-007797.md), filed Mar 11, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d44f57a9-b2c2-4a4b-8760-9f3a7b872c3e) ## About the filer - CIK: 884269 - Tickers: APT - Exchange: NYSE - SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.